Antibiotics are a double-edged sword—they should be as toxic as possible to pathogenic bacteria while being harmless to the ...

Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Proteins are the foundation of all life we currently know. With their virtually limitless diversity, they can perform a broad ...

Stifel initiated coverage of Structure Therapeutics (GPCR) with a Buy rating and $50 price target Structure aims to expand the reach of ...

with a Buy rating and $50 price target Structure aims to expand the reach of metabolic treatments across the large, heterogeneous obesity landscape by way of its drug discovery platform of oral ...

Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.

Researchers may have found a new target in fighting malaria -- a cholesterol ... "By focusing on PfNCR1, scientists could develop drugs that the parasite finds difficult to develop resistance ...

ACCG-2671 demonstrates potent target engagement and robust weight ... a robust pipeline and is leveraging its advanced structure-based drug discovery platform, underscoring its commitment to ...

Glaucoma, the leading cause of blindness, is often marked by loss of retinal ganglion cells (RGCs). Necroptosis, a form of ...

The starting point for all structure-based design work, whether ligand or protein based, is the choice of a suitable target. Antimicrobial-drug targets should be essential, have a unique function ...

Biological research investigating drug-target interaction necessitates a ... In order to confirm that HG9-91-01 can protect the retinal structure in patients with AOH, the team plans on conducting ...